Vor Bio trem-cel relapse-rate remains low, says Oppenheimer

After Vor Bio (VOR) announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg, Oppenheimer analyst Matthew Biegler noted that only two of 15 patients, versus two of 10 in the last update, relapsed and said engraftment data remains “encouraging.” Following the update, the firm reiterates its Outperform rating and $8 price target on Vor Bio shares.